The University of California, San Diego (UCSD) was awarded a $10,223,791 Definitive Federal Contract by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. This contract does not have a set-aside designation. As part of this effort, UCSD has issued subcontracts to several companies, including Life Technologies Corporation, Inimmune Corp, Luminex Corp, Miltenyi Biotec, Inc., and Biotage, LLC, to provide a range of specialized products and services such as assay optimization, adjuvant formulation, flow cytometry instruments, and automated chromatography systems. This contract supports the NIAID's Vaccine Adjuvant Discovery Program, which aims to develop new vaccine adjuvants that can enhance immune responses against pathogens relevant to human disease.
Generated 7/6/24, 9:10 AM